Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIG_Announcement_OMHE_is_Diving_into_$36Billion_Pain_Management_GlobalMarket
Link To News
Huge_News>>>>>>OMHE_Developed_Cannabinoid-Based_Medicine
Link To News
OMHE has an advanced Biotech R&D lab and scientists have developed cannabinoid-based drug therapies / medicines. Clinical Trial Started
Click to Read News>>>OMHE had announced all this earlier this year
OMHE_PPS@4c_Supplying_OverTheCounter_MJ_Ointments_to_Doctors_Clinics_Hospitals
OMHE PPS HAS BEEN RISING DAILY.......
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE Announced Adding $7Million in Revenue
$7Million in Revenue Add News Link
OMHE_with_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
My Next Prediction
IMLFF will look for collaboration with other companies, who have already applied to FDA for CBD Drug registration. IMLFF has huge, very valuable Bio database.
Welcome to the party texasholdem
HERE is HOW OMHE REACHED TO THIS FDA APPROVAL STEP
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
FDA_will_Approve_OMHEs_Marijuana_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS Ready to Rise to $1
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine_Therapeutics
OMHE_is_The_Champion_of_6_Pharma_Industries_Applying _for_FDA_Approval_for_MMJ_Medicine
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS is Rising and will soon be $1
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Thx_Tinman...Even_Bigger_Updates_Are_On_The_Way....Look @ OMHE CEO, R&D Team, Experience, Vision, Plan Execution Speed...OMHE is a GOLD MINE
OMHE MMJ R&D Team
On 5/10/2017, SAB was formed and CEO had promised to expand "this Board with an elite group of industry, academic, and government experts" and on 6/1/2017, OMHE showed its commitment by inducting 2nd member to SAB. OMHE updated about another scientist in 11/14/2017 Letter.
SAB Member # 1: Dr. Arkady Uryash, MD, PhD
Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.
SAB Member # 2: Dr. Lawrence E. Samuels, MD
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
SAB Member # 3: Dr. Karyemaitre Aliffe, MD
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
OMHE_with_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
$7Million in Revenue Add News Link
OMHE_has_CBD_Drug_@FDA_for_Approval_Today_PRd_Received_$7Mln_AntiAging_Cream_Order
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
OMHE Announced Adding $7Million in Revenue
OMHE has been rising since its NOV 2017 announcement of CBD Pain medicine development and DEC 2017 update on the initiation of FDA approval process. NOW PUBLISHED THIS FASCINATING $7Million Rev Add news in an already $10Million Rev.
$7Million in Revenue Add News Link
OMHE_a_MMJ_Biotech_Company_Received_$7Million_Order_for_Anti_Aging_Cream
$7Million in Revenue Add News Link
IMLFF is working on the cure of several diseases
Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.
MMJ_Biotech_Companies PPS Will Surge Hundred_Times+ in 2018
Good times are coming as hidden treasures of MJ are being uncovered!!
IMLFF=BioinformaticsTool+BiosynthesisSYS+DrugDevelopmentProgram
The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools.
2018 is going to be the Year of MMJ Pharma Companies
InMed Pharmaceuticals Inc. is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs.
OMHE_is_Adding_$7Million_in_Rev_By_Supplying_OverTheCounter_MJ_Ointments_to_Doctors, Clinics & Hospitals
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_PPS@4c_Supplying_OverTheCounter_MJ_Ointments_to_Doctors_Clinics_Hospitals
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
KALTF: Recent Surprised PPS Surge
During first week of Dec 2017, unexplained PPS rise was seen. KALTF management released a letter to shareholder to share their feelings.
KALTF Letter
KALTF: 2018 is the Year of CBD Medicine Development
Several Pharma companies are working on the development of cannabinoid therapeutics; some have developed CBD drugs, and are early to advanced stages on FDA approval.
CBD Medicine will be widely used in the absence of opioids.
KALTF is Working in Most Profitable MMJ Biotech Industry
Kalytera Therapeutics is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease ("GvHD"). Kalytera is also developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.
KALTF CEO Additional Board and Management
KALTF News
OMHE IS THE LEADER OF THE MMJ BIOTECH INDUSTRY
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017 results, which they did!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed Over The Counter cannabinoid biotherapeutics/medicine
* OMHE is marketing/selling Over The Counter cannabinoid biotherapeutics/medicine to Doctor’s offices, clinics, and hospitals to ensure appropriate usage
* OMHE to Collaborate/joint venture with one of the largest European cannabis companies.
* Licensed Medical marijuana cultivation about to start.
* OMHE applied to FDA for in-house developed prescription MJ Medicine approval
* OMHE PPS is heading to $ 1 PPS
OMHE_is_The_Champion_of_6_Pharma_Industries_Applying _for_FDA_Approval_for_MMJ_Medicine
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS is Rising and will soon be $1
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Approval_Also_has_OverTheCounter_CBD_Meds
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Projected_Revenues_FY2018=$8_to_$10Million_&_FY2019=$15_to_$17Million_More_Rev_Add_MMJ_Products_are_in_the_pipeline
June-13-2017: Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line & Revenue Add to $10Million Total - Read Here
Dec-05-2017: MMJ Medicine Development, FDA Approval Plan & $7 Million Revenue Add News - Read Here
FDA_will_Approve_OMHEs_Marijuana_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS Ready to Rise to $1
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
NMUS Presentation
NMUS is making progress; however, needs some more time...
Link to News
NMUS
NMUS is working with Univ. of MISSISSIPPI
NMUS is in the early stages of Research
NMUS Update
2018 is for MMJ Biotech Companies
Any company that has successfully developed MMJ Medicine and going to FDA for approval will see huge surge in their PPS
NOV/DEC2017_OMHE_PRs_Brought_PPS_from_1c_TO_4c_Next_PR_Will_Take_it_to_THE_MOON
11/14/2017 MMJ Medicine Development and Future Plans Updates News
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
FDA_will_Approve_OMHEs_CBD_based_Pain_Medicine_in_2018
OMHE's PLAN is SOLID!!!
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1